Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as ...

AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

The company plans to invest billions in a new drug manufacturing hub in Virginia, dedicated to chronic disease treatments, alongside additional facilities in California, Indiana, Maryland, ...

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...

British pharmaceuticals giant AstraZeneca has revealed it plans to invest $50 billion (£37 billion) in America over the next ...

AstraZeneca has announced a $50 billion investment in the United States by 2030, creating tens of thousands of new, highly ...

AstraZeneca (Cambridge, U.K.) announced $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines ...

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...